
Mylan Labs to acquire King Pharmaceuticals; deal cancelled
Executive Summary
Mylan Laboratories Inc. has agreed to acquire King Pharmaceuticals for about $4.2bn. Under terms of the stock swap, King shareholders receive 0.9 Mylan common shares for each King common held. Based on Mylan's average share price prior to announcement, it paid $17.33 per King share, a 65% premium to market.
Deal Industry
- Pharmaceuticals
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Stock
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice